Compare CHCT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | BWAY |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.6M | 337.9M |
| IPO Year | 2015 | 2019 |
| Metric | CHCT | BWAY |
|---|---|---|
| Price | $16.23 | $18.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $18.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 216.2K | 72.6K |
| Earning Date | 02-17-2026 | 11-11-2025 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $119,547,000.00 | $49,094,000.00 |
| Revenue This Year | $6.97 | $330.76 |
| Revenue Next Year | $5.98 | $22.24 |
| P/E Ratio | ★ N/A | $61.62 |
| Revenue Growth | 3.40 | ★ 27.08 |
| 52 Week Low | $13.23 | $7.84 |
| 52 Week High | $20.87 | $19.80 |
| Indicator | CHCT | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 63.07 |
| Support Level | $15.57 | $18.31 |
| Resistance Level | $16.28 | $19.80 |
| Average True Range (ATR) | 0.31 | 0.82 |
| MACD | 0.03 | 0.21 |
| Stochastic Oscillator | 97.10 | 80.68 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.